Supernus, Inc. (INDV) stock

INDVNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SUPN

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 6/30

$35.37+0.12 (+0.34%)

Close on Oct 30, 2026Market cap $4.17BP/E 9.9Yield –

Earnings

Supernus's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Feb 25, 2027

Q4 FY2026 · estimated, before the open

Revenue, Q3 FY2026

$356.00M

+13.4% on a year earlier

Non-GAAP diluted earnings per share, Q3 FY2026

$1.32

$0.72 a year earlier

Latest guidance

Issued

Oct 29, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of Supernus's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q4 FY2026ended Dec 31, 2026	Feb 25, 2027Expected	–	–	–	–	–
Q3 FY2026ended Sep 30, 2026	Oct 29, 2026before the open	$356.00M	+13.4%	$1.12	$1.32	Release
Q2 FY2026ended Jun 30, 2026	Aug 3, 2026before the open	$343.00M	+13.6%	$0.98	$1.15	Release
Q1 FY2026ended Mar 31, 2026	Apr 30, 2026before the open	$317.00M	+19.2%	$0.69	$0.96	Release
Q4 FY2025ended Dec 31, 2025	Feb 26, 2026before the open	$358.00M	–	–	–	Release
Q3 FY2025ended Sep 30, 2025	Oct 30, 2025before the open	$314.00M	–	$0.33	$0.72	Release
Q2 FY2025ended Jun 30, 2025	Jul 31, 2025before the open	$302.00M	–	$0.14	$0.51	Release
Q1 FY2025ended Mar 31, 2025	Apr 24, 2025after the close	$266.00M	–	$0.38	$0.41	Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Supernus's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
Net RevenueGAAP	FY2026	$1.30B – $1.37B	–	New	Oct 29, 2026
Net Revenue	FY2026	$1.30B – $1.37B	$1.22B – $1.29B	Raised	Aug 3, 2026
Adjusted EBITDAnon-GAAP	FY2026	$700.00M – $740.00M	–	New	Oct 29, 2026
adjusted EBITDA growthnon-GAAP	FY2026	+50%	–	New	Apr 30, 2026
Adjusted EBITDA*non-GAAP	FY2026	$700.00M – $740.00M	$620.00M – $660.00M	Raised	Aug 3, 2026
Non-GAAP Operating Expensesnon-GAAP	FY2026	$430.00M – $450.00M	–	New	Oct 29, 2026
Non-GAAP Operating Expenses*non-GAAP	FY2026	$430.00M – $450.00M	$430.00M – $450.00M	Reaffirmed	Aug 3, 2026
Total SUBLOCADE Net RevenueGAAP	FY2026	$1.01B – $1.05B	–	New	Oct 29, 2026
total SUBLOCADE net revenue growth	FY2026	+13%	–	New	Apr 30, 2026

Guidance vs results

The last range Supernus gave before each report, against the figure it then reported. Full years add up the four quarters.

Period	Metric	Guidance	Actual	Result
FY2025	Revenue	$825.00M – $845.00M	$1.24BΣ4Q	Above range

Guidance history

Every forecast Supernus put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Oct 29, 2026	Adjusted EBITDA	FY2026	$700.00M – $740.00M	New
Oct 29, 2026	Non-GAAP Operating Expenses	FY2026	$430.00M – $450.00M	New
Oct 29, 2026	Total SUBLOCADE Net Revenue	FY2026	$1.01B – $1.05B	New
Oct 29, 2026	Net Revenue	FY2026	$1.30B – $1.37B	New
Aug 3, 2026	Adjusted EBITDA*	FY2026	$700.00M – $740.00M	Raised
Aug 3, 2026	Non-GAAP Operating Expenses*	FY2026	$430.00M – $450.00M	Reaffirmed
Aug 3, 2026	Net Revenue	FY2026	$1.30B – $1.37B	Raised
Aug 3, 2026	Total SUBLOCADE Net Revenue	FY2026	$1.01B – $1.05B	Lowered
Apr 30, 2026	adjusted EBITDA growth	FY2026	+50%	New
Apr 30, 2026	Adjusted EBITDA	FY2026	$620.00M – $660.00M	New
Apr 30, 2026	Non-GAAP Operating Expenses	FY2026	$430.00M – $450.00M	New
Apr 30, 2026	total SUBLOCADE net revenue growth	FY2026	+13%	New
Apr 30, 2026	Net Revenue	FY2026	$1.22B – $1.29B	New
Apr 30, 2026	Total SUBLOCADE Net Revenue	FY2026	$950.00M – $990.00M	Lowered
Oct 30, 2025	Adjusted EBITDA*	FY2025	$400.00M – $420.00M	New
Oct 30, 2025	Non-GAAP R&D*	FY2025	$75.00M – $80.00M	Lowered
Oct 30, 2025	Non-GAAP SG&A*	FY2025	$510.00M – $520.00M	New
Oct 30, 2025	SUBLOCADE NR	FY2025	$825.00M – $845.00M	Lowered
Oct 30, 2025	Net Revenue (NR)	FY2025	$1.18B – $1.22B	New
Jul 31, 2025	Adjusted EBITDA*	FY2025	$275.00M – $300.00M	New
Jul 31, 2025	Net Revenue (NR)	FY2025	$1.03B – $1.08B	New
Apr 24, 2025	Non-GAAP Operating Income	FY2025	$185.00M – $225.00M	New
Apr 24, 2025	Non-GAAP R&D	FY2025	-$90.00M – -$85.00M	Raised
Apr 24, 2025	Non-GAAP SG&A	FY2025	-$535.00M – -$525.00M	New
Apr 24, 2025	Net Revenue (NR)	FY2025	$955.00M – $1.03B	New
Apr 24, 2025	OPVEE NR	FY2025	$10.00M – $15.00M	Lowered
Apr 24, 2025	SUBLOCADE NR	FY2025	$725.00M – $765.00M	Lowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.